• Sanofi to acquire Kymab for up to $1.45bn pharmatimes
    January 12, 2021
    Sanofi will acquire Cambridge, UK-based biopharmaceutical company Kymab in a potential $1.45bn deal, which will see the French pharma add Kymab’s monoclonal antibody (mAB) KY1005 to its pipeline.
PharmaSources Customer Service